HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kilfeather, S. Search for Related Content PubMed PubMed Citation Articles by Kilfeather, S.

5-Lipoxygenase Inhibitors for the Treatment of COPD^*

^* From the Institute for Cardiovascular and Respiratory Pharmaceutical Development, University of Sunderland, Tyne & Wear, Sunderland, UK.

Correspondence to: Stephen Kilfeather, PhD, Institute for Cardiovascular and Respiratory Pharmaceutical Development, University of Sunderland, Tyne & Wear, Sunderland, SR1 3SD, United Kingdom; e-mail: SkilfeatherICRPD{at}aol.com

The potential for leukotrienes as mediators to target in the development of novel therapies for diseases such as COPD is underscored by their inflammatory behavior and the capacity of leukotriene receptor antagonists and synthesis inhibitors to reduce inflammatory responses when administered in vivo. Airway neutrophilia in COPD patients is believed to be a contributing source of inflammation and is associated with airway remodeling. The presence of neutrophils is mediated in part by leukotriene B₄ (LTB₄), and the capacity for LTB₄ alone to replicate many aspects of neutrophilic inflammation has provided the focus of drug development toward its specific antagonism. More recently, the potential involvement of the monocyte-macrophage lineage in the etiology of COPD has received growing attention as a target for leukotriene inhibition. The future avenues for exploration of leukotriene inhibition could have been expanded by the realization that 5-lipoxygenase activity is primarily located at the nuclear membrane and the existence of differing cell surface and nuclear receptors to LTB₄. The success of compounds under development in this and other anti-inflammatory classes, however, depends as much on the evolution of clinical studies designed to test the "proof of concept" in efficacy through the examination of surrogate markers or physiologic readouts of changes in lung function.

Key Words: antagonist • COPD • 5-lipoxygenase • 5-lipoxygenase inhibitor • leukotriene • leukotriene B₄ • neutrophil

This article has been cited by other articles:

				G. Riccioni, C. Di Ilio, P. Conti, T. C. Theoharides, and N. D'Orazio Advances in Therapy with Antileukotriene Drugs Ann. Clin. Lab. Sci., October 1, 2004; 34(4): 379 - 387. [Abstract] [Full Text] [PDF]